CLL

Oncology·MeSH: Leukemia, Lymphocytic, Chronic, B-Cell

Prevalence

30.0 / 100K

34 drugs in development·17 companies·6 clinical trials

Drug Pipeline by Phase

Approved(5)

Drug	Company
belrapzo	EAGLE PHARMACEUTICALS, INC. (EGRX)
brukinsa	BeOne Medicines Ltd. (ONC)
clonoSEQ	Adaptive Biotechnologies Corp (ADPT)
venetoclax	DR REDDYS LABORATORIES LTD (RDY)
zydelig	GILEAD SCIENCES, INC. (GILD)

Phase 3(18)

Drug	Company
bendamustine	BeOne Medicines Ltd. (ONC)
bendamustine	BeOne Medicines Ltd. (ONC)
Bendamustine	BeOne Medicines Ltd. (ONC)
bexobrutideg	Nurix Therapeutics, Inc. (NRIX)
btk inhibitor	ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
btk-cdac	BeOne Medicines Ltd. (ONC)
Idelalisib	BeOne Medicines Ltd. (ONC)
Idelalisib	Merus N.V. (MRUS)
lisaftoclax +btk inhibitor	ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
liso-cel	CELGENE CORP /DE/ (CELG)
obinutuzumab	BeOne Medicines Ltd. (ONC)
obinutuzumab	BeOne Medicines Ltd. (ONC)
Obinutuzumab	BeOne Medicines Ltd. (ONC)
Obinutuzumab	AbbVie Inc. (ABBV)
Roginolisib	ENANTA PHARMACEUTICALS INC (ENTA)
Venetoclax	ASTRAZENECA PLC (AZN)
Venetoclax	BeOne Medicines Ltd. (ONC)
zilovertamab	Oncternal Therapeutics, Inc. (ONCT)

Phase 1(9)

Drug	Company
BP1002	BIO-PATH HOLDINGS, INC. (BPTH)
jcar014	Juno Therapeutics, Inc. (JUNO)
jcar017	Juno Therapeutics, Inc. (JUNO)
lisaftoclax	ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
mb-106	MUSTANG BIO, INC. (MBIO)
NX-2127	Nurix Therapeutics, Inc. (NRIX)
NX-5948	Keros Therapeutics, Inc. (KROS)
NX-5948	Nurix Therapeutics, Inc. (NRIX)
zelebrudomide	Nurix Therapeutics, Inc. (NRIX)

Phase 4(2)

Drug	Company
Acalabrutinib	ASTRAZENECA PLC (AZN)
Zanubrutinib	BeOne Medicines Ltd. (ONC)

BioSniper tracks 34 drugs in development for CLL across 17 companies.

There are 6 clinical trials targeting CLL tracked by BioSniper.

The estimated prevalence of CLL is approximately 30.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.